Clinical Study of the BioVentrix Revivent TC for the Treatment of Ischemic Cardiomyopathy

Inclusion Criteria: * Age 18 - 80; * Left Ventricular Ejection Fraction (LVEF) \>15% and ≤ 45%; * New York Heart Association (NYHA) Functional Class II-IV; * Left Ventricular End Systolic Volume (LVESVI) ≥60 cc/m² but ≤ 120 cc/ m² * Contiguous acontractile (akinetic and/or dyskinetic) scar located in the antero-septal, apical (may extend laterally) regions of the left ventricle as evidenced by a Cardiac Magnetic Resonance (CMR) or Computed Tomography (CT); * Maintained standard medical management for at least 90 days, and at stable target (or maximum tolerated) dosages; * Willing and competent to complete informed consent; * Viability of myocardium in regions remote from area of intended scar exclusion as evidenced by CMR or CT; * Agree to required follow-up visits Exclusion Criteria: * Calcified ventricular wall in the area of intended scar exclusion as verified by echocardiography or equivalent; * Thrombus or intra-ventricular mass in the left atrium or ventricle as verified by echocardiography or equivalent; * Cardiac Resynchronization Therapy (CRT) device placement ≤ 60 days prior to enrollment; * Significant diastolic dysfunction, defined as a pseudo-normal Doppler filling pattern with E/A ratio \> 2; * Thin walled, paradoxically moving septal scar that would preclude successful support of the anchor pairs as evidenced by CMR; * Cardiac valve disease which, in the opinion of the investigator, will require surgery; * Intolerance or unwillingness to take anti-coagulation medication; * Functioning pacemaker leads in antero-apical right ventricle, which, in the opinion of the investigator, would interfere with anchor placement; * Pulmonary Arterial Pressure \> 60 mm Hg via echo; * Myocardial Infarction within 90 days prior to enrollment; * Previous Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA) which resulted, in the opinion of the investigator, in a significant residual neurological deficit; * Aorto iliac disease that would preclude fem-fem bypass. * Previous right neck surgery, previous pericardiotomy, previous left chest surgery; * Co-morbid disease process with life expectancy of less than one year; * Patients with lung, kidney and/or liver transplant; * Chronic renal failure with a serum creatinine \>2 mg/dL; * Inoperable coronary disease with significant ischemia; * Pregnant or planning to become pregnant during the study; * Enrolled in any concurrent study other than observational. * Previous left thoracotomy * Pulmonary disease that would preclude single lung ventilation